A comparison of human G-Csf and human Gm-Csf given concurrently with anti-cancer chemotherapy.
Granulocyte-colony-stimulating factor (G-Csf) and granulocyte-macrophagecolony-stimulating factor (GM-Csf) were each given concurrently with continuous infusion of doxorubicin, ifosphamide, or vinorelbine. Both cytokines enabled the dose intensity of these three anti-tumor agents to be substantially increased without an increase in drug toxicity. The effect of Gm-Csf as a stimulant of dendritic cell production and function was noted.
Weiss
Arthur J
AJ
Division of Medical Oncology, Hahnemann University Hospital, Philadelphia, PA, USA. ajw@acadia.net
Lackman
Richard D
RD
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D003713:Dendritic Cells / Q000378:metabolism; D004317:Doxorubicin / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000096:biosynthesis*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis*; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D016896:Treatment Outcome; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D004317:Doxorubicin; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000077235:Vinorelbine; D007069:Ifosfamide